CEO COMMENTS
Kristina Torfgård comments Q1 report 2025
“The first quarter of 2025 has been one of our most dynamic to date, marked by significant regulatory progress, promising clinical results, and the deepening of strategically important partnerships, all collectively strengthening our position. Following an in-depth analysis of the topline data for pirepemat presented during the quarter, we can confidently affirm that all of our development programs continue to make evident progress and bring us closer to our goal – to provide new, effective treatments for people living with Parkinson’s disease.
Key Milestones During the Quarter:
- Promising results from the Phase I study with IRL757 enable the next step in clinical development – a study in patients with Parkinson’s and apathy. Our strategic collaboration with MSRD/Otsuka and the Michael J. Fox Foundation plays an important role in advancing the development of IRL757.
- The regulatory progress for mesdopetam lays a strong foundation for the upcoming Phase III program and deepened discussions with potential partners.
- Study data on pirepemat show a statistically significant and clinically meaningful reduction in fall rate, linked to the plasma concentrations of the drug.
Together, these advances demonstrate that we are well on our way to realizing our vision and creating value for patients, partners and shareholders.”
LATEST REPORTS
The subscription period in IRLABS’s rights issue of shares commence today
Today, on 3 July 2025, the subscription period commences in IRLAB Therapeutics AB’s (“IRLAB” or the “Company”) rights issue of shares of series A with preferential rights for existing shareholders up to approximately MSEK 136 (the “Rights Issue”), which was resolved and announced on 24 June 2025. The subscription period for the Rights Issue will run until and including 17 July 2025. However, please note that certain banks and nominees may apply an earlier deadline for subscription. Shareholders are therefore advised to check with their bank or nominee regarding any earlier response deadline that may apply.
Read More >
Presentation at Aktiespararna
Presentation by Kristina Torfgård, CEO, at Aktiespararna (in Swedish), held June 10, 2025.
Read More >FINANCIAL CALENDAR
NEXT
August 27 2025
Interim Report January – June 2025